Company name: Octarine Bio
Description: Developer of cannabinoids and psilocybin derivatives intended to improve the health and well-being of people. The company harness synthetic biology to develop functionally superior cannabinoid and psychedelic tryptamine derivatives, enabling healthcare institutions to treat neurological and psychological disorders.
Year founded: 2018
Industry: Healthcare | Group: | Code:
Start up capital raised (USD Million):
Business status: Generating Revenue
Ownership: Privately Held (backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: The company raised an undisclosed amount of seed funding from Vækstfonden on March 11, 2020. The funds will be used for research and seveopment.
Number of active investors:
Profile last updated: 12-Mar-2020
Last known valuation:
Last known valuation date: